Bio-Techne ( (TECH)) just unveiled an announcement. At its annual meeting, Bio-Techne Corporation announced the election of nine directors and the approval of executive compensation and KPMG LLP as ...

Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

According to a Feb. 17, 2026, SEC filing, Hollow Brook Wealth Management LLC sold out its entire position in Bio-Techne (NASDAQ:TECH) during the fourth quarter of 2025. The fund divested 174,677 ...

Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment ...

Bio-Techne (NASDAQ:TECH) is preparing to release its quarterly earnings on Wednesday, 2026-02-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

A large exercise of company stock options by Robert V Baumgartner, Director at Bio-Techne TECH was disclosed in a new SEC filing on August 27, as part of an insider exercise. What Happened: A notable ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...